Skip to main content
Prashant Kapoor, MD, Oncology, Rochester, MN

Prashant Kapoor MD

Hematologic Oncology


Assistant Professor, Oncology, Mayo Medical School

Join to View Full Profile
  • 200 1st St SwRochester, MN 55905

  • Phone+1 507-284-2511

Dr. Kapoor is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2009 - 2013
  • Ascension Illinois/Saint Francis
    Ascension Illinois/Saint FrancisResidency, Internal Medicine, 2000 - 2003
  • Seth G.S. Medical College
    Seth G.S. Medical CollegeClass of 1999

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 2004 - 2026
  • ND State Medical License
    ND State Medical License 2004 - 2009
  • IL State Medical License
    IL State Medical License 2000 - 2008
  • Hematology
    American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Centricity Enterprise, GE Healthcare, 2014-2017
  • CMS Meaningful Use Stage 2 Certification Mayo Clinic Electronic Notes, Mayo Clinic, 2014-2017
  • CMS Meaningful Use Stage 2 Certification Centricity Patient Online, GE Healthcare, 2014-2017

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Impact of Prior Diagnosis of Monoclonal Gammopathy on Outcomes in Newly Diagnosed Multiple Myeloma  
    S Vincent Rajkumar, Yi L Hwa, Wilson I Gonsalves, Francis K Buadi, Angela Dispenzieri, Prashant Kapoor, Miriam A Hobbs, Martha Q Lacy, John A Lust, Robert A Kyle, Mori..., Nature
  • Safety and Efficacy of Propylene Glycol-Free Melphalan as Conditioning in Patients with AL Amyloidosis Undergoing Stem Cell Transplantation  
    Nelson Leung, Prashant Kapoor, Taxiarchis V Kourelis, Eli Muchtar, Angela Dispenzieri, M Hasib Sidiqi, Martha Q Lacy, Wilson I Gonsalves, Shaji K Kumar, Mohammed A Alj..., Nature
  • Relapse After Complete Response in Newly Diagnosed Multiple Myeloma: Implications of Duration of Response and Patterns of Relapse  
    Angela Dispenzieri, Francis K Buadi, Morie A Gertz, Martha Q Lacy, Nelson Leung, Amie L Fonder, Wilson I Gonsalves, Yi Lisa Hwa, Taxiarchis Kourelis, Surbhi Sidana, Ro..., Nature

Abstracts/Posters

  • Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis
    Prashant Kapoor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant
    Prashant Kapoor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Waldenstr_m Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?
    Prashant Kapoor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Minimal Residual Disease in Hematologic Malignancies: Testing Considerations and Challenges 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Long-Term Survivorship with Active Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Simplified rIPSS-WM Improves Risk Stratification in Waldenström Macroglobulinemia
    Simplified rIPSS-WM Improves Risk Stratification in Waldenström MacroglobulinemiaSeptember 9th, 2024
  • Predictors of Short-Term Survival in Waldenström Macroglobulinemia
    Predictors of Short-Term Survival in Waldenström MacroglobulinemiaJuly 14th, 2020
  • Researchers Devise a Progression Risk-Based Classification for Patients with Asymptomatic Waldenström Macroglobulinemia
    Researchers Devise a Progression Risk-Based Classification for Patients with Asymptomatic Waldenström MacroglobulinemiaApril 23rd, 2019

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: